VistaGen Therapeutics News and Activities

VistaGen Therapeutics is a company listed under the stock ticker VTGN (US).

View the org chart displaying its 25 main executives

Most searched biographies at VistaGen Therapeutics

• Shawn Singh, Chief Executive Officer and Director
• Mary Rotunno, Director
• Maggie Fitzpatrick, Chairman of the Board

Popular executive movements at VistaGen Therapeutics

• Angel Angelov has joined the company as Chief Medical Officer  (posted on May 19 2026).
• Nick Tressler has joined the company as Chief Financial Officer  (posted on December 1 2025).
• Paul Edick has joined the company as Director  (posted on October 29 2025).

Click here to view some more movements at VistaGen Therapeutics

Create your alert
to follow the executive moves at VistaGen Therapeutics.

VistaGen Therapeutics has 2,403 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• GNI has announced the acquisition of Ayumi Pharmaceutical  (posted on June 12 2026).
• Humacyte has just announced a $50 Million fundraising (posted on June 12 2026).
• Beren Therapeutics has just announced a $300 Million fundraising (posted on June 12 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by VistaGen Therapeutics

• Vistagen to Participate in Jefferies 2026 Global Healthcare Conference | Vistagen Therapeutics, Inc
• Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer | Vistagen Therapeutics, Inc
• Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | Vistagen Therapeutics, Inc
• Press Releases | Vistagen Therapeutics, Inc
• Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder | Vistagen Therapeutics, Inc
• Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder | Vistagen Therapeutics, Inc
• Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause | Vistagen Therapeutics, Inc
• Vistagen to Participate in Upcoming Investor Conferences | Vistagen Therapeutics, Inc
• Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference | Vistagen Therapeutics, Inc
• Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update | Vistagen Therapeutics, Inc
• View more press releases Close

Social media about VistaGen Therapeutics

• VistaGen Therapeutics on Wikipedia, Google News & Yahoo Finance
• VistaGen Therapeutics on LinkedIn, X (Twitter) & YouTube